- Home
- AZI vs TLSA Comparison
AZI vs TLSA Comparison
Compare AZI & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AZI | TLSA |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | China | United Kingdom |
| Employees | 53 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 155.2M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | AZI | TLSA |
|---|---|---|
| Price | $2.10 | $1.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 15.0M | 141.1K |
| Earning Date | 02-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.73 |
| 52 Week High | $4.60 | $2.60 |
Technical Indicators
Market Signals| Indicator | AZI | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 63.11 | 46.51 |
| Support Level | $1.94 | N/A |
| Resistance Level | $3.25 | $1.62 |
| Average True Range (ATR) | 0.20 | 0.12 |
| MACD | 0.15 | -0.00 |
| Stochastic Oscillator | 64.72 | 36.84 |
Price Performance
Historical ComparisonAbout AZI Autozi Internet Technology (Global) Ltd. Class A Ordinary Shares
Autozi Internet Technology (Global) Ltd provides high-quality, affordable, and professional one-stop automotive products and services through online and offline channels in China. Leveraging its online supply chain cloud platform, SaaS platforms, and the network of MBS stores, it has established an ecosystem of lifecycle automotive services by connecting automotive manufacturers, auto parts manufacturers, and insurance companies with MBS stores and various automotive owners. Its business segments include new car sales, auto parts and auto accessories sales, and automotive insurance-related services. The majority of revenue is from the auto parts & auto accessories sales.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.